4D Molecular Therapeutics/$FDMT
1D1W1MYTD1Y5YMAX
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
- Ticker
- $FDMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 196
- Headquarters
- EmeryVille, United States
FDMT Metrics
BasicAdvanced
$804M
-
-$2.77
2.69
-
Price and volume
Market cap
$804M
Beta
2.69
52-week high
$15.03
52-week low
$5.97
Average daily volume
722K
Financial strength
Current ratio
8.033
Quick ratio
7.676
Long term debt to equity
8.302
Total debt to equity
9.62
Profitability
EBITDA (TTM)
-188.89
Gross margin (TTM)
-157.70%
Net profit margin (TTM)
-194.74%
Operating margin (TTM)
-210.76%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-25.09%
Return on equity (TTM)
-43.25%
Valuation
Price to revenue (TTM)
10.212
Price to book
1.97
Price to tangible book (TTM)
1.97
Price to free cash flow (TTM)
-6.024
Free cash flow yield (TTM)
-16.60%
Free cash flow per share (TTM)
-2.414
Growth
Revenue change (TTM)
278,712.12%
Earnings per share change (TTM)
-21.20%
3-year revenue growth (CAGR)
242.75%
3-year earnings per share growth (CAGR)
-5.35%
What the Analysts think about FDMT
Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.
FDMT Financial Performance
Revenues and expenses
FDMT Earnings Performance
Company profitability
FDMT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.